Volume 10, Issue 3

New Insights into Pulmonary Exacerbations

In this issue:

Where’s the evidence about managing pulmonary exacerbations in people with cystic fibrosis? What actually defines an exacerbation? Do females and males respond differently to treatment? Should two antipseudomonal antibiotics remain the standard of care?  

Join us in this issue of eCysticFibrosis Review as Dr. D.B. Sanders from the Indiana University School of Medicine describes the ongoing research into exacerbation management. 

Learning objectives:

  • Discuss the impact of pulmonary exacerbation treatment decisions on pulmonary exacerbation outcomes in people with cystic fibrosis. 
  • Describe the differences in pulmonary exacerbation treatment responses between men and women with CF.  


D.B. Sanders, MD, MS
D.B. Sanders, MD, MS

Associate Professor of Pediatrics
Department of Pediatrics
Indiana University School of Medicine
Cystic Fibrosis Center Director
Division of Pediatric Pulmonology, Allergy and Sleep Medicine
Riley Hospital for Children

Program Directors:

Noah Lechtzin, MD, MHA

Director, Adult Cystic Fibrosis Program
Associate Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Peter J. Mogayzel, Jr., MD, PhD

Professor of Pediatrics
Director, Cystic Fibrosis Center
Johns Hopkins University School of Medicine
Baltimore, MD

Donna Peeler, RN

Clinical Nurse 
Pediatric Clinic Coordinator 
Johns Hopkins Cystic Fibrosis Center 
Baltimore, MD

Length of activity:

1.0 hour Physicians
1.0 contact hour Nurses

Launch date: July 19, 2022
Expiration date: July 18, 2024